{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:55:18Z","timestamp":1791179718840,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.2515\/therapie:2008037","type":"journal-article","created":{"date-parts":[[2008,6,19]],"date-time":"2008-06-19T07:13:16Z","timestamp":1213859596000},"page":"119-127","source":"Crossref","is-referenced-by-count":9,"title":["La consommation de cannabis chez les sujets pr\u00e9sentant un abus, une pharmacod\u00e9pendance ou sous traitement de substitution de la d\u00e9pendance aux opiac\u00e9s : donn\u00e9es OPPIDUM 2006 et principales tendances depuis 2004 du r\u00e9seau des Centres d\u2019\u00c9valuation et d\u2019Information sur la Pharmacod\u00e9pendance (CEIP)"],"prefix":"10.1016","volume":"63","author":[{"given":"Elisabeth","family":"Frauger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronica","family":"Orl\u00e9ans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Jolliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"le R\u00e9seau des CEIP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2008037_bb0010","series-title":"Cannabis, donn\u00e9es essentielles","author":"Observatoire Fran\u00e7ais des Drogues et des Toxicomanies","year":"2007"},{"key":"10.2515\/therapie:2008037_bb0015","series-title":"Tendances n\u00b050 Saint-Denis, OFDT","first-page":"6","article-title":"Premier bilan des \u201cconsultations cannabis\u201d","author":"Obradovic","year":"2006"},{"key":"10.2515\/therapie:2008037_bb0020","series-title":"Enqu\u00eate sur les personnes accueillies en consultations cannabis en 2005","first-page":"100p","author":"Obradovic","year":"2006"},{"key":"10.2515\/therapie:2008037_bb0025","series-title":"Ph\u00e9nom\u00e8nes \u00e9mergents li\u00e9s aux drogues en 2005 - Rapport TREND Janv","author":"Observatoire Fran\u00e7ais des Drogues et des Toxicomanies","year":"2007"},{"key":"10.2515\/therapie:2008037_bb0030","first-page":"3","article-title":"WHO Expert Committee on Drug Dependence","volume":"741","author":"Anonymous","year":"1987","journal-title":"Twenty-third Report"},{"key":"10.2515\/therapie:2008037_bb0035","series-title":"Circulaire DPHM\/03\/09\/90\/1 du 1er octobre 1990 relative \u00e0 la mise en place des centres d\u2019\u00e9valuation et d\u2019information sur les pharmacod\u00e9pendances","author":"Minist\u00e8re des Affaires Sociales et de la Solidarit\u00e9","year":"1990"},{"key":"10.2515\/therapie:2008037_bb0040","series-title":"D\u00e9cret n\u00b099-249 du 31 mars 1999 relatif aux substances v\u00e9n\u00e9neuses et \u00e0 l\u2019organisation de l\u2019\u00e9valuation de la pharmacod\u00e9pendance, modifiant le code de la sant\u00e9 publique. JO 1999 1 avril","first-page":"4847","author":"Minist\u00e8re des Affaires Sociales et de la Solidarit\u00e9","year":"1999"},{"key":"10.2515\/therapie:2008037_bb0045","first-page":"25","article-title":"Dispositif d\u2019\u00e9valuation de la pharmacod\u00e9pendance en France","volume":"1","author":"Gatignol","year":"2000","journal-title":"Le courrier des addictions Mars"},{"key":"10.2515\/therapie:2008037_bb0050","first-page":"15","article-title":"Le syst\u00e8me fran\u00e7ais d\u2019\u00e9valuation de la pharmacod\u00e9pendance et de l\u2019abus : cons\u00e9cration juridique","volume":"56","author":"Baumevieille","year":"2001","journal-title":"Therapie"},{"issue":"1","key":"10.2515\/therapie:2008037_bb0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s002280050246","article-title":"Falsified or forged medical prescriptions as an indicator of pharmacodependence: a pilot study. Community pharmacists of the Midi-Pyrenees","volume":"52","author":"Lapeyre-Mestre","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie:2008037_bb0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00228-001-0412-7","article-title":"Forged medical prescriptions in a community pharmacy network in Midi-Pyrenees area: assessment of a falsification ratio","volume":"57","author":"Llau","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.2515\/therapie:2008037_bb0065","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00002018-200730030-00007","article-title":"French Network of Centers for Evaluation and Information Pharmacodependence (CEIP). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey","volume":"30","author":"Boeuf","year":"2007","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2008037_bb0070","first-page":"16","article-title":"DRAMES, outil d\u2019identification des causes de d\u00e9c\u00e8s chez les toxicomanes : r\u00e9sultats des \u00e9tudes 2002-2006","volume":"1","author":"Boulos","year":"2008","journal-title":"Le courrier des addictions"},{"key":"10.2515\/therapie:2008037_bb0075","series-title":"DRAMES, nouvel outil pour conna\u00eetre les causes des d\u00e9c\u00e8s chez les toxicomanes : bilan de cinq \u00e9tudes Le courrier des Addictions 1","author":"Arditti","year":"2006"},{"key":"10.2515\/therapie:2008037_bb0080","first-page":"164","article-title":"La soumission m\u00e9dicamenteuse","volume":"3","author":"Djezzar","year":"2001","journal-title":"Le courrier des Addictions"},{"issue":"6","key":"10.2515\/therapie:2008037_bb0085","first-page":"609","article-title":"Essai de mise au point d\u2019une m\u00e9thode de surveillance des produits utilis\u00e9s par les toxicomanes consultant dans les services d\u2019accueil","volume":"48","author":"San Marco","year":"1993","journal-title":"Therapie"},{"issue":"5","key":"10.2515\/therapie:2008037_bb0090","first-page":"586","article-title":"Observation des produits psychotropes illicites ou d\u00e9tourn\u00e9s de leur utilisation m\u00e9dicamenteuse (OPPIDUM) : cinq ans de surveillance des produits consomm\u00e9s par les toxicomanes \u00e0 Marseille","volume":"51","author":"San Marco","year":"1996","journal-title":"Therapie"},{"key":"10.2515\/therapie:2008037_bb0095","series-title":"Toxibase revue documentaire","first-page":"52","article-title":"Le programme OPPIDUM des Centres d\u2019\u00c9valuation et d\u2019Information sur les Pharmacod\u00e9pendances (CEIP) : historique et apports","author":"Thirion","year":"1998"},{"issue":"2","key":"10.2515\/therapie:2008037_bb0100","first-page":"243","article-title":"D\u00e9pendance aux psychotropes et traitements de substitution : tendances r\u00e9centes. A propos de l\u2019enqu\u00eate OPPIDUM des Centres d\u2019\u00c9valuation et d\u2019Information sur les Pharmacod\u00e9pendances (CEIP) d\u2019Octobre 1997","volume":"54","author":"Thirion","year":"1999","journal-title":"Therapie"},{"key":"10.2515\/therapie:2008037_bb0105","first-page":"A10","article-title":"Traitements de substitution de la d\u00e9pendance aux opiac\u00e9s dans les centres de soins : le programme OPPIDUM des Centres d\u2019\u00c9valuation et d\u2019Information sur la Pharmacod\u00e9pendance","volume":"151","author":"Thirion","year":"2000","journal-title":"Ann Med Interne (Paris)"},{"key":"10.2515\/therapie:2008037_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000050711","article-title":"Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme","volume":"7","author":"Thirion","year":"2001","journal-title":"Eur Addict Res"},{"key":"10.2515\/therapie:2008037_bb0115","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1046\/j.1360-0443.2001.961014337.x","article-title":"Comparison of methadone and high dosage buprenorphine users in French care centres","volume":"96","author":"Barrau","year":"2001","journal-title":"Addiction"},{"issue":"6","key":"10.2515\/therapie:2008037_bb0120","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2515\/therapie:2006089","article-title":"Scoring pharmacodependence seriousness: a novel CEIP\u2019s evaluation tool","volume":"61","author":"Victorri-Vigneau","year":"2006","journal-title":"Therapie"},{"issue":"2","key":"10.2515\/therapie:2008037_bb0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1365-2125.2007.02861.x","article-title":"Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmaco dependence (CEIP) network survey","volume":"64","author":"Victorri-Vigneau","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie:2008037_bb0130","first-page":"89","article-title":"Les usagers fr\u00e9quents de cannabis, \u00e9l\u00e9ments descriptifs, France, 2004","volume":"20","author":"Bello","year":"2005","journal-title":"BEH"},{"key":"10.2515\/therapie:2008037_bb0135","series-title":"Drogues et d\u00e9pendance, donn\u00e9es essentielles","author":"Observatoire Fran\u00e7ais des Drogues et des Toxicomanies","year":"2005"},{"issue":"3","key":"10.2515\/therapie:2008037_bb0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-200205000-00008","article-title":"Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine","volume":"17","author":"Zullino","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.2515\/therapie:2008037_bb0145","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00196109","article-title":"Smoking and body weight influence the clearance of chlorpromazine","volume":"46","author":"Chetty","year":"1994","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716305455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716305455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:28:22Z","timestamp":1554276502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716305455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0040595716305455"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2008037","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}